The prognostic nomogram constructed based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 is expected to better assess the prognosis of patients with HCC and provide new candidate molecules. The gene discussed is SLC41A3; the disease is hepatocellular carcinoma.